Frequency of self-monitoring of blood glucose in patients with type 2 diabetes: association with hypoglycaemic events

Farmer, Andrew; Balman, Elizabeth; Gadsby, Roger; Moffatt, Jane; Cradock, Sue; McEwen, Lisa M.; Jameson, K.

doi:10.1185/03007990802473062

Cited by 28 publications

(19 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current results also validate existing data indicating that patients who have experienced NSHEs fear future hypoglycemic events [14,19], and that NSHEs are associated with patient-initiated changes to diabetes self-management. These include an increased frequency of SMBG (self-monitoring of blood glucose) testing and greater use of blood glucose strips [16,17], as well as adjustments to insulin dose and/or increased food consumption [19]. In this study, across all four countries, costs for extra blood glucose strips, as well as patient outof-pocket expenses for food items to control NSHEs, ranged from ϳ$17 to $35 USD.…”

Section: Discussionmentioning

confidence: 97%

“…In addition, hypoglycemic events, and concerns regarding future events, can lead patients with diabetes to maintain higher glucose levels overall and/or fail to use adequate doses of insulin or oral antidiabetic medications [12][13][14][15]. Patient concerns about potential hypoglycemia are also associated with an increased frequency of self-monitoring of blood glucose [16] and an attendant increase in blood glucose strip use [17].…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes Management

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 98%

The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes Management

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The previous UK studies 22,23 , carried out by a survey, offered initial insights into the glucose testing behaviors in (2008) of patients with type 2 diabetes treated with non-insulin concluded that evidence is not convincing for a clinically meaningful effect of clinical management by self-monitoring of blood glucose levels compared with management without self-monitoring. Additionally, the recent UK HTA assessment, where studies included adult patients with type 2 diabetes on any oral treatment or on a combination of regimens including lifestyle, oral agents, or once-daily basal insulin, concluded that SMBG is of limited clinical effectiveness in improving glycemic control in those on oral agents or diet alone, and therefore is unlikely to be cost-effective.…”

Section: Discussionmentioning

confidence: 99%

“…There has been some recent research on the satisfaction and frequency of SMBG in the UK 22,23 . A 2008 study found that, among patients with type 2 diabetes, those patients treated with insulin used SMBG at a greater frequency than those patients not treated with insulin (median 10-times per week vs 4-times per week; p50.01) 22 .…”

Section: Introductionmentioning

confidence: 99%

“…A 2008 study found that, among patients with type 2 diabetes, those patients treated with insulin used SMBG at a greater frequency than those patients not treated with insulin (median 10-times per week vs 4-times per week; p50.01) 22 . In a 2010 survey study, over 80% of patients reported a high satisfaction with the usefulness of SMBG and reported feeling more 'in control' of the management of their diabetes 23 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Frequency of blood glucose testing among insulin-treated diabetes mellitus patients in the United Kingdom

Lee¹,

Smith²,

Chubb³

et al. 2014

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis

Kamalinia

Josse

Donio

et al. 2019

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

Objectives: For patients with type 2 diabetes, newer antihyperglycaemic agents (AHA), including the dipeptidyl peptidase IV inhibitors (DPP4i), glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium glucose co-transporter 2 inhibitors (SGLT2i) offer a lower risk of hypoglycaemia relative to sulfonylurea or insulin.However, it is not clear how AHA compare to placebo on risk of any hypoglycaemia.This study evaluates the risk of any and severe hypoglycaemia with AHA and metformin relative to placebo. Design: A systematic review and meta-analysis was conducted of randomized, placebo-controlled trials ≥12 weeks in duration. MEDLINE, Embase and the Cochrane Library were searched up to April 16, 2019. Studies allowing use of other diabetes medications were excluded. Mantel-Haenszel risk ratio with 95% confidence intervals were used to pool estimates based on class of AHA and number of concomitant therapies used.Patients: Eligible studies enrolled patients with type 2 diabetes ≥18 years of age.Results: 144 studies met our inclusion criteria. Any hypoglycaemia was not increased with AHA when used as monotherapy (DPP4i (RR 1.12; 95% CI 0.81-1.56), GLP1RA (1.77; 0.91-3.46), SGLT2i (1.34; 0.83-2.15)), or as add-on to metformin (DPP4i (0.95; 0.67-1.35), GLP1RA (1.24; 0.80-1.91), SGLT2i (1.29; 0.91-1.83)) or as triple therapy (1.13; 0.67-1.91). However, metformin monotherapy (1.73; 1.02-2.94) and dual therapy initiation (3.56; 1.79-7.10) was associated with an increased risk of any hypoglycaemia. Severe hypoglycaemia was rare not increased for any comparisons. Conclusions:Metformin and the simultaneous initiation of dual therapy, but not AHA used alone or as single add-on combination therapy, was associated with an increased risk of any hypoglycaemia relative to placebo. K E Y W O R D S diabetes mellitus, type 2, dipeptidyl peptidase IV inhibitor, glucagon-like peptide-1 receptor agonist, hypoglycaemia, sodium glucose co-transporter 2 inhibitor S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section. How to cite this article: Kamalinia S, Josse RG, Donio PJ, Leduc L, Shah BR, Tobe SW. Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis. Endocrinol Diab Metab. 2020;3:e00100. https ://doi.

show abstract

Frequency of self-monitoring of blood glucose in patients with type 2 diabetes: association with hypoglycaemic events

Cited by 28 publications

References 16 publications

The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes Management

The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes Management

Frequency of blood glucose testing among insulin-treated diabetes mellitus patients in the United Kingdom

Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis

Contact Info

Product

Resources

About